Bayer stock reacts to FDA cancer drug approval and Roundup settlement test

Published on 09/11/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock is trading around EUR 48.80 on Xetra as of September 10, 2026, while analysts at Deutsche Bank keep a buy rating with a EUR 60 target. The shares also face a pivotal USD 7.25 billion Roundup settlement test in a Missouri court on September 11, 2026.

Flatlay auf weißem Untergrund: weiße runde Tabletten, Marmorstößel, grünes Pflanzenblatt, Glasflakon und gedrucktes DNA-Doppelhelix-Diagramm; Beschriftungskarte mit Text PHARMA — Top-down-Arrangement: weiße Tabletten, Mörser, grünes Blatt, DNA-Diagramm, Beschriftungskarte PHARMA, Illustration mit AI erstellt.

Bayer AG stock (ISIN DE000BAY0017) closed at EUR 48.81 on Xetra on September 10, 2026, down about 0.9 percent from the previous session’s EUR 49.26 finish according to Xetra closing data cited by Welt.

FDA approval for sevabertinib strengthens oncology pipeline

As Ad-hoc-news reports on September 11, 2026, Bayer recently received accelerated approval from the US Food and Drug Administration for its lung cancer drug sevabertinib, a first-line treatment option for adults with non-small cell lung cancer carrying a specific HER2 mutation.

According to MarketScreener on September 10, 2026, the accelerated FDA approval for sevabertinib covers first-line use in non-small cell lung cancer and is seen as a meaningful addition to Bayer’s oncology portfolio.

Roundup settlement faces pivotal court test

Beyond the drug pipeline, Bayer is also navigating a key legal milestone. Reuters reported on September 11, 2026 that Bayer’s Monsanto unit is seeking approval in a Missouri state court for a USD 7.25 billion settlement designed to resolve tens of thousands of US lawsuits alleging that Roundup causes cancer.

According to the Reuters report, Judge Timothy Boyer will examine the settlement framework and hear objections from some plaintiffs’ attorneys who argue their clients should not be compelled into the proposed arrangement, making the hearing a pivotal test of Bayer’s effort to draw a line under years of Roundup litigation.

Analyst support and valuation backdrop

Ad-hoc-news notes that, as of September 10, 2026, Bayer stock at EUR 48.81 on Xetra trades clearly below the latest analyst targets, with Deutsche Bank Research reiterating a buy rating and a price target of EUR 60 and Barclays raising its target to EUR 70, both in euro terms.

According to MarketScreener, Deutsche Bank on September 10, 2026 maintained its buy recommendation on Bayer with a EUR 60 target, while Barclays on September 8, 2026 lifted its target to EUR 70 and rates the shares as overweight.

Recent price action and market data

Price reports from finanzen.ch on September 11, 2026 show intraday Xetra trading around EUR 48.65 to EUR 48.82, with Bayer shares moving between a small loss of 0.1 percent and a gain of 0.2 percent during the midday and morning sessions.

According to finanzen.ch, Bayer stood at EUR 48.65 on Xetra at 12:28 on September 11, 2026, about 0.1 percent in the red, while a separate finanzen.ch snapshot shows the shares at EUR 48.82 at 09:28, up 0.2 percent.

Layer C: latest closing price and investor lens

For investors, the most recent complete reference point remains the Xetra close at EUR 48.81 on September 10, 2026, about 0.9 percent below the prior EUR 49.26 finish and still notably under the Deutsche Bank target of EUR 60 and the Barclays target of EUR 70.